Evaluation of cytotoxic effects induced by bcl-2 and bcl-xL antisense-oligodeoxynucleotides in normal urothelium and transitional cell carcinoma

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1419-1423

  Gabiel, Ute ^a   Bolenz, Christian ^a   Becker, Andreas ^a   Schaaf, Axel ^a   Steidler, Annette ^a   Trojan, Lutz ^a   Weiss, Christel ^a   Michel, Maurice Stephan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Chemotherapy; Gene therapy; Oligodeoxy ribonucleotides; Toxicity test; Transitional cell carcinoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BCL X;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN TARGETING; TRANSITIONAL CELL CARCINOMA; UROTHELIUM; BLADDER TUMOR; CELL SURVIVAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC TRANSCRIPTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; PATHOLOGY; TUMOR CELL LINE;

BCL-X PROTEIN; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 59249107122     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000161     Document Type: Article

References (17)

1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 465-475, 2006.
2. Sylvester RJ, Oosterlinck W and van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171: 2186-2190, 2004.
3. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608, 2005.
4. Lebedeva I, Raffo A, Rando R, Ojwang J, Cossum P and Stein CA: Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 166: 461-469, 2001.
5. Hong JH, Lee E, Hong J, Shin YJ and Ahn H: Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int 90: 113-117, 2002.
6. Uhlmann E, Ryte A and Peyman A: Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev 7: 345-350, 1997.
7. Fuessel S, Meye A, Kraemer K, Kunze D, Hakenberg OW and Wirth MP: Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma. Eur Urol 51: 315-326, 2007.
8. Schaaf A, Sagi S, Langbein S, Trojan L, Alken P and Michel MS: Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bcl-2 antisense oligonucleotides. Urol Oncol 22: 188-192, 2004.
9. Bolenz C, Becker A, Trojan L, Schaaf A, Cao Y, Weiss C, Alken P and Michel MS: Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides. Urol Oncol 25: 476-482, 2007.
10. Hopkins-Donaldson S, Cathomas R, Simoes-Wust AP, Kurtz S, Belyanskaya L, Stahel RA and Zangemeister-Wittke U: Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. Int J Cancer 106: 160-166, 2003.
11. Duggan BJ, Maxwell P, Kelly JD, Canning P, Anderson NH, Keane PF, Johnston SR and Williamson KE: The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 166: 1098-1105, 2001.
12. Matthes E and Lehmann C: Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res 27: 1152-1158, 1999.
13. Krieg AM and Stein CA: Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev 5: 241, 1995.
14. Benimetskaya L, Lai JC, Khvorova A, Wu S, Hua E, Miller P, Zhang LM and Stein CA: Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Clin Cancer Res 10: 8371-8379, 2004.
15. Kausch I and Bohle A: Antisense oligonucleotide therapy in urology. J Urol 168: 239-247, 2002.
16. Korkolopoulou P, Lazaris A, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P, Thomas-Tsagli E and Davaris P: Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival. Eur Urol 41: 274-283, 2002.
17. Duggan BJ, Gray S, Johnston SR, Williamson K, Miyaki H and Gleave M: The role of antisense oligonucleotides in the treatment of bladder cancer. Urol Res 30: 137-147, 2002.